贝达药业申请H股上市并刊登申请资料

Core Viewpoint - Beida Pharmaceutical has submitted an application for the issuance of overseas listed shares (H-shares) and listing on the main board of the Hong Kong Stock Exchange as of September 29, 2025 [1] Financial Performance - For the first half of 2025, Beida Pharmaceutical reported revenue of 1.731 billion yuan and a net profit attributable to shareholders of 140 million yuan [1]